Navigation Links
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:1/29/2009

MOUNTAIN VIEW, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has consolidated its operations, with a primary focus on the continued rapid development of AZ-004 (Staccato loxapine). The restructuring includes a workforce reduction of 52 employees, representing approximately 33% of the Company's total workforce. In addition, Alexza and Endo Pharmaceuticals, Inc. have agreed to mutually terminate their development agreement for AZ-003 (Staccato fentanyl), a product development candidate that has completed Phase 1 clinical testing. Alexza does not intend to commit additional resources to AZ-003 during 2009.

Alexza expects to reduce its expenses by approximately $21.5 million, net of severance costs, for fiscal year 2009, compared to fiscal year 2008, and approximately $11.1 million for fiscal year 2010, compared to fiscal year 2009. As of September 30, 2008, Alexza had $78.0 million in cash and investments. As a result of this consolidation, Alexza projects that it has available cash resources to maintain its currently planned operations into the second quarter of 2010.

AZ-004 is Alexza's lead product candidate, which is in late-stage clinical development for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. The Company has previously announced positive results in both of its two Phase 3 trials of AZ-004, and expects to submit a New Drug Application for AZ-004 in early 2010. AZ-004 is being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital, LLC.

"The most difficult aspect of these hard decisions is the fact that Alexza has accomplished much in the past five years as a result of an incredible amount of hard work and dedication by many emp
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 ... the 3rd Annual Disruptive Innovations to Advance Clinical Trials ... Copley Plaza Hotel in Boston, MA. , Disruptive ... Janssen Pharmaceuticals and more share bold approaches to reduce ... , “Disruptive innovation needs to be big, or ...
(Date:5/22/2013)... Genedata, a leading provider of advanced ... life science research, today announced AB Enzymes will ... bioinformatics platform for strain genome data management on ... Enzymes, one of the world’s oldest and best-known ... Selector accompanied by bioinformatics consulting services. Genedata Selector, ...
(Date:5/22/2013)... Chicago, IL (PRWEB) May 22, 2013 Alton ... thetelegraph.com dated May 15, 2013 said that their presence ... help other bed bug sufferers avoid such big spending, My ... bugs inexpensively. , It was said in the report ... an exterminator, MCP related. Apart from that, its employees also ...
(Date:5/21/2013)... England , May 22, 2013 ... novel drug-only formulation of glycopyrronium bromide designed using Prosonix, ... pharmaceutical company developing a portfolio of inhaled Respiratory ... clinical study with PSX1002 that will assess its effect ... of doses in patients with moderate to severe chronic ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... ... Clinical Applications, BOTHELL, Wash., Nov. ... developer and marketer of proprietary,hypothermic storage and cryopreservation media products ... a Master File to the,United States Food and Drug Administration ...
... Nov. 5 On Friday, November 7, 2008,at ... members,of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: CTIC ... conference call to discuss the Company,s 2008,third quarter ... Numbers Friday, November 7 8:30 a.m. ...
... Inc.,(Nasdaq: TELK ) reported a net loss of ... ended September 30, 2008, compared with a net loss ... period in 2007. The,$8.0 million net loss includes a ... with an auction reset feature, or,auction rate securities, which ...
Cached Biology Technology:BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 2BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 3Telik Announces Financial Results for 2008 Third Quarter 2Telik Announces Financial Results for 2008 Third Quarter 3Telik Announces Financial Results for 2008 Third Quarter 4
(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
(Date:5/21/2013)... COLUMBIA, Mo. Cancers of all types become most ... body. Once cancer has reached this stage, it becomes ... numerous tumors that can develop. Now, researchers at the ... radioactive nanoparticles that target lymphoma tumor cells wherever they ... professor of oncology in the MU College of Veterinary ...
(Date:5/21/2013)... Widely available in pharmacies and health stores, phosphatidylserine ... oysters, and soy. Proven to improve cognition and ... older people experiencing memory impairment. Now a team ... Bochner of Tel Aviv University,s Department of ... same supplement improves the functioning of genes involved ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2
... Wash. An international team of scientists from Italy, France, ... sequence of the domestic apple genome in the current issue ... genome sequence for apple will allow scientists to more rapidly ... which genes and gene variants provide disease or drought resistance ...
... a chronic and often disabling condition. Despite modern ... to the patients and their relatives and take ... and societal expenditure. The diagnosis of ... structure and changes in neurotransmission, with increased dopamine ...
... (August 27, 2010) Although having a high body ... cardiovascular disease, researchers are only beginning to understand how ... of the disease. Now, a study of a subset ... (KEEPS), suggests that as BMI increases, so do platelet ...
Cached Biology News:Core knowledge of tree fruit expands with apple genome sequencing 2Core knowledge of tree fruit expands with apple genome sequencing 3Body mass index and thrombogenic factors in newly menopausal women 2Body mass index and thrombogenic factors in newly menopausal women 3
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
...
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
Biology Products: